Cover Image
市場調查報告書

癌症診斷全球市場:第6版

The World Market for Cancer Diagnostics, 6th Edition (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)

出版商 Kalorama Information 商品編碼 270517
出版日期 內容資訊 英文 861 Pages
訂單完成後即時交付
價格
Back to Top
癌症診斷全球市場:第6版 The World Market for Cancer Diagnostics, 6th Edition (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)
出版日期: 2015年09月11日 內容資訊: 英文 861 Pages
簡介

本報告調查全球癌症診斷市場,提供以IVD (體外診斷) 區分之組織學/細胞學、免疫測定、流式細胞術、快速檢測、分子化驗、組織陣列、CTC、藥理診斷,以及分子相關分析資料。並彙整市場與趨勢分析、精準醫療中個人化癌症檢測的進步、以及主要企業簡介。

第1章 摘要整理

第2章 簡介

  • 背景
  • 癌症-診斷和治療管理
  • 觀點

第3章 癌症診斷商業化的市場課題

  • 背景
  • 癌症統計:全球現象
  • 癌症全球市場推估
  • 全球癌症:篩選、政府支援計劃
    • 美國
    • 加拿大
    • 歐洲
    • 中國
    • 印度
    • 非洲
  • 次世代癌症檢查商業化
  • 美國臨床分子檢測核銷編碼
    • 檢測服務:癌症創新路線
  • 癌症檢測規範要求
  • 基因專利、檢測商業化
  • 搭配檢測開發的影響
  • 檢測驗收中醫生角色

第4章 實現未來癌症診斷的技術趨勢

  • 背景
  • 生物標記:臨床研究課題
  • 小型、多重化驗
  • 非侵入性工具登場
  • 生物資訊學:資訊數據
  • 用於癌症診斷的新技術
  • 體內細胞與分子影像作用
    • 概要
    • Digital PCR
    • 質量分析
    • 染色體分析
    • 次世代定序
    • 樣品製備與系統自動化
    • 體內細胞與分子影像作用

第5章 市場分析:癌症檢測

  • 癌症診斷市場
  • 主要供應商與值得關注企業
  • 收購、聯盟及合作
  • 篩選:爭論仍持續
  • 分散式癌症檢測展望
  • 癌症特異性檢測
    • 乳癌
    • 結腸癌
    • 肺癌
    • 卵巢癌
    • 胰臟癌

第6章 臨床化學癌症檢測

  • 主要細胞功能臨床化學檢測
  • 化學分析儀及試劑主要企業

第7章 免疫測定癌症檢測

  • 癌症管理中免疫測定所扮演的角色
    • 廣泛被利用的腫瘤標記
  • 實驗室基礎化驗
  • POC:快速檢測
    • 結腸癌
    • 前列腺癌
    • 膀胱癌

第8章 組織與細胞基礎癌症檢測

  • 背景
  • 市場概要
    • 抹片檢查& HPV檢測
    • 組織微陣列
    • 細胞訊號傳導路徑檢測

第9章 市場分析:流式細胞術中的癌症檢測

  • 市場規模
    • 因應癌症檢測的主要流式細胞術創新

第10章 市場分析:癌症檢測中的循環腫瘤細胞檢測(CTC)

  • 市場規模

第11章 癌症分子化驗

  • 背景
    • RNA:核糖核酸
    • 甲基化基因 (meDNA) 模組
    • 循環血漿 DNA
    • 微量殘存疾病 (MRD)

第12章 精準醫療中個人化癌症檢測的進步

  • 背景
    • 藥物診斷學歷史
    • 治療藥監測免疫測定

第13章 結論與策略展望

  • 結論與策略展望
  • 市場需求未滿足

第14章 企業簡介:主要IVD企業癌症檢測

第15章 企業簡介:循環腫瘤細胞 (CTC) 專門企業

第16章 企業簡介:組織與細胞檢測專門企業

第17章 企業簡介:癌症蛋白質標記專門企業

第18章 企業簡介:分子檢測專門企業

第19章 企業簡介:癌症檢測服務供應商

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: KLI5686737

Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The market for cancer testing are comprehensively covered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 5th. Edition. This report, authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:

  • Histology/Cytology
  • Immunoassays
  • Flow Cytometry
  • Rapid Tests
  • Molecular Assays
  • Tissue Arrays
  • Circulating Tumor Cells
  • Pharmacodiagnostics, Molecular

Cancer Testing: Constant Innovation

Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up.

  • New imaging modalities and digital analysis of x-ray mammograms are looking to improve the accuracy of breast cancer screening. These same imaging techniques are being used to screen patients for the metastasis of cancer from the primary site.
  • Lab testing for new cancer biomarkers - hormone, receptor and protein assays - improve the detection of cancer in patients that present with symptoms. These are now available in multiplexed tests that make better use of tissue samples.
  • With developments in the analysis of circulating cancer cells and cell free DNA in peripheral blood they are poised to help in the screening of high risk individuals.
  • Improved immunohistochemical stains and in situ hybridization make detection of cancer cells in biopsied tissue more effective. The use next generation analysis of individual tumor cells including sequencing, mass spectrometry and PCR further enhance cancer testing in tissues.
  • Bioinformatic analysis of gene and protein patterns detected in tumor cells and peripheral blood is proving to be a big breakthrough in cancer diagnosis. The technology has pinpointed gene and protein targets that will make up the next generation of cancer tumor marker panels.
  • The next big advances are related to tests based on the detection of circulating nucleic acid molecules and RNA and DNA methylation patterns.

Complete Market and Trend Analysis

Kalorama Information reports are always based on primary research of the market with particular attention to important market trends that are more important to understand than today's numbers. Shara Rosen not only defines the marketplace and provides market numbers, but her report also examines trends that are driving cancer testing now and determining where it will go in the future. Some of the trends examined in this report include:

  • Commercializing Next Generation Cancer Tests
  • Clinical Molecular Test Reimbursement Coding In The U.S.
  • Regulatory Requirements of Cancer Tests
  • Gene Patents and Test Commercialization
  • The Physician's Role in Test Acceptance
  • Biomarkers: Issues in Research to Clinic
  • Miniaturization and Multiplexed Assays
  • The Emergence Of Non-Invasive Tools
  • Bioinformatics - Data To Information
  • Digital PCR, Mass Spectrometry, Next-Generation Sequencing
  • Sample Preparation and System Automation
  • The Role of In Vivo Cellular and Molecular Imaging

and Analyst Conclusions, Strategy Implications and Unmet Market Needs Based on an analysis of these trends, the report includes a 'Technology Forecast' to 2025 that takes each particular technology used now in solid tumor testing and predicts its future role.

Personalized Cancer Testing and Advances In Precision

The phenomenon of test personalization comes under many guises - pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them.

This report covers those trends and has tables describing the following:

  • Most Common Cancer Drug/Gene Mutation Combinations
  • Selected Pharmacodiagnostic Histology Tests
  • Chemotherapy Resistance Tests
  • Innovations in Personalized Molecular Tests for Cancer
  • Therapeutic Drug Monitoring Immunoassays
  • Major Protein And Molecular Markers Used In Tissue Staining

Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies

This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemias - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail.

Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe -- N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific.

The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis.

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections. Companies profiled include the following:

  • Abbott Diagnostics
  • Beckman Coulter Inc./Danaher
  • Becton, Dickinson and Company
  • bioMérieux Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • AB Sciex
  • Leica
  • GE Healthcare
  • Gen-Probe Inc.
  • Hologic, Inc.
  • IRIS International, Inc.
  • Novartis Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Sysmex Corporation
  • Abnova
  • ApoCell, Inc.
  • Biocept, Inc.
  • Clearbridge BioMedics
  • Cynvenio Biosystems, Inc.
  • Epic Sciences Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • NaturalNano, Inc.
  • On-Q-ity
  • ProKyma Technologies
  • RareCyte, Inc.
  • ScreenCell
  • Sony DADC Biosciences
  • Veridex, LLC
  • WaveSense LLC
  • Advanced Cell Diagnostics
  • Amoy Diagnostics Co. Ltd.
  • Applied Spectral Imaging
  • Biocare Medical, LLC
  • Biodis Biotechnology
  • BioMarker Strategies
  • Biomoda Inc.
  • BioView Ltd.
  • Bruker Corporation
  • CCC Diagnostics, Inc.
  • Caliper Life Sciences
  • Celerus Diagnostics
  • Cernostics, Inc.
  • ChipDX, LLC
  • Circadian Technologies Limited
  • Cymogen Dx, LLC
  • Dako A/S
  • Diagnostic Biosystems (DBS)
  • DVS Sciences Inc.
  • DxTerity Diagnostics Inc.
  • Halo Healthcare Inc. (formerly NeoMatrix, LLC)
  • HistoRx, Inc.
  • Horizon Discovery Ltd
  • iKaryos Diagnostics
  • IncellDx, Inc.
  • Leica Biosystems
  • Metamark Genetics, Inc.
  • Nodality, Inc.
  • Norchip
  • Oxford Cancer Biomarkers
  • Philips Handheld Diagnostics
  • QuantuMDx
  • Theranostics Health Inc.
  • Ventana Medical Systems Inc.
  • Arbor Vita Corporation
  • Axela Biosensors, Inc.
  • Binding Site (The)
  • BioCurex, Inc.
  • Biomerica Inc.
  • Cellmid Ltd.
  • Eutropics Pharmaceuticals
  • Fujirebio Diagnostics, Inc.
  • GeneTex
  • Gold Standard Diagnostics:
  • HealthLinx Limited
  • Immunomedics
  • MabCure Inc.
  • Matrix-Bio
  • Nano Discovery Inc.
  • Oncimmune USA LLC
  • OncoCyte Corp.
  • OncoHealth Corp.
  • OPKO Health, Inc.
  • Polymedco Cancer Diagnostic Products, LLC
  • Proteomika S.L.
  • Radient Pharmaceuticals Corporation
  • Saladax Biomedical, Inc.
  • ScheBo-Biotech AG
  • Wako Diagnostics
  • Abcodia
  • Adaptive Biotechnologies Corporation
  • Affymetrix, Inc.
  • Agilent Technologies Inc.
  • ArcticDx Inc.
  • Arrayit Diagnostics Inc.
  • Asuragen, Inc.
  • Autogenomics Inc.
  • Biocartis
  • Biodesix, Inc.
  • Cepheid
  • DiagnoCure
  • Diagnoplex SA
  • Enzo Biochem Inc.
  • Epigenomics AG
  • Falcon Genomics, Inc.
  • GeneCentric Diagnostics, Inc.
  • GeneNews Limited
  • Genetic Technologies Limited
  • Genomica S.A.U.
  • Illumina Inc.
  • Inform Genomics, Inc.
  • Ipsogen SA
  • Life Technologies
  • TrovaGene, Inc.
  • VolitionRx Limited

And Many More Companies..

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Test Segments
  • Geographic Distribution
  • Market Trends

CHAPTER TWO: INTRODUCTION

  • Background
  • Cancer - Diagnosis And Therapy Management
  • Point of View

CHAPTER THREE: MARKET ISSUES IN THE COMMERCIALIZATION OF CANCER DIAGNOSTICS

  • Background
  • Demographics of cancer, A Global Phenomenon
  • Cancer World Market Estimate
  • Cancer in the World - Screening and Government Supported Programs
  • United States
  • Canada
  • Europe
  • China
  • India
  • Africa
  • Commercializing Next Generation Cancer Tests
  • Clinical Molecular Test Reimbursement Coding In The U.S.
  • Test Services - Route For Cancer Innovation
  • Regulatory Requirements of Cancer Tests
  • Gene Patents and Test Commercialization
  • Impact of Companion Test Development
  • The Physician's Role in Test Acceptance

CHAPTER FOUR: TECHNOLOGICAL TRENDS THAT ENABLE THE FUTURE OF CANCER DIAGNOSTICS

  • Background
  • Biomarkers: Issues in Research to Clinic
  • Miniaturization and Multiplexed Assays
  • The Emergence Of Non-Invasive Tools
  • Bioinformatics - Data To Information
  • New Technologies Applied To Cancer Diagnostics
  • Overview
  • Digital PCR
  • Mass Spectrometry
  • Chromosome Analysis
  • Next-Generation Sequencing
  • Sample Preparation and System Automation
  • The Role of In Vivo Cellular and Molecular Imaging

CHAPTER FIVE: MARKET ANALYSIS - CANCER TESTING

  • The Market for Cancer Diagnostics
  • Major Vendors and Companies to Watch
  • Acquisitions, Alliances and Collaborations
  • Screening - The Debate Continues
  • Prospects for Decentralized Cancer Testing
  • Cancer Specific Tests
  • Breast Cancer
  • Colon Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

CHAPTER SIX: CANCER TESTS IN CLINICAL CHEMISTRY

  • Selected Tissue Function Clinical Chemistry Tests
  • Major Players In Chemistry Analyzers and Reagents

CHAPTER SEVEN: IMMUNOASSAY CANCER TESTS

  • Role Of Immunoassays In Cancer Management
  • Selected Widely Used Tumor Markers
  • Lab-Based Assays
  • POC - rapid tests
  • Colon Cancer
  • Prostate Cancer
  • Bladder Cancer

CHAPTER EIGHT: TISSUE- AND CELL-BASED CANCER TESTS

  • Background
  • Market Overview
  • Pap Smear & HPV Testing
  • Tissue Microarrays
  • Cell Signaling Pathway Testing

CHAPTER NINE: MARKET ANALYSIS - CANCER TESTS IN FLOW CYTOMETRY

  • Market Size
  • Selected Flow Cytometry Innovations For Cancer Testing

CHAPTER TEN:MARKET ANALYSIS - CIRCULATING TUMOR CELLS IN CANCER DIAGNOSTICS

  • Market Size
  • Selected CTC Capture And Analysis Systems

CHAPTER ELEVEN: - CANCER MOLECULAR ASSAYS

  • Background
  • RNA - Ribonucleic Acid
  • Methylated Gene (meDNA) Patterns
  • Circulating Plasma DNA
  • Minimal Residual Disease

CHAPTER TWELVE: PERSONALIZED CANCER TESTING ADVANCES IN PRECISION

  • Background
  • Pharmacodiagnostic Histology
  • Therapeutic Drug Monitoring Immunoassays

CHAPTER THIRTEEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

  • Conclusions and Strategic Implications
  • Unmet Market Needs

CHAPTER FOURTEEN: COMPANY PROFILES: MAJOR IVD COMPANY CANCER TESTING

  • Abbott Diagnostics
  • Molecular Histology
  • Companion Tests
  • Molecular Diagnostics
  • Core Lab
  • Hematology
  • Alere
  • NMP22
  • Beckman Coulter Inc./Danaher
  • Core Lab
  • Immunoassays
  • Histology
  • Flow Cytometry
  • Becton, Dickinson and Company (BD)
  • Histology
  • Molecular
  • Flow Cytometry
  • bioMérieux Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • AB Sciex
  • Leica
  • GE Healthcare
  • Cell Imaging
  • Sequencing
  • Gen-Probe Inc.
  • HPV
  • Hologic, Inc.
  • IRIS International, Inc.
  • Novartis Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer, Inc.
  • CLIA Lab
  • QIAGEN N.V.
  • Histology
  • Roche Diagnostics
  • PCR
  • Companion Tests
  • Hematological Cancers
  • Core Lab
  • Siemens Healthcare Diagnostics
  • Histology
  • Sysmex Corporation

CHAPTER FIFTEEN: COMPANY PROFILES: CIRCULATING TUMOR CELLS SPECIALISTS

  • Abnova
  • ApoCell, Inc.
  • Biocept, Inc.
  • Clearbridge BioMedics
  • Cynvenio Biosystems, Inc.
  • Epic Sciences Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • NaturalNano, Inc.
  • On-Q-ity
  • ProKyma Technologies
  • RareCyte, Inc.
  • ScreenCell
  • Sony DADC Biosciences
  • Veridex, LLC
  • WaveSense LLC

CHAPTER SIXTEEN: COMPANY PROFILES: TISSUE AND CELL TEST SPECIALISTS

  • Advanced Cell Diagnostics
  • Amoy Diagnostics Co. Ltd.
  • Applied Spectral Imaging
  • Biocare Medical, LLC
  • Biodis Biotechnology
  • BioMarker Strategies
  • Biomoda Inc.
  • BioView Ltd.
  • Bruker Corporation
  • CCC Diagnostics, Inc.
  • Caliper Life Sciences
  • Celerus Diagnostics
  • Cernostics, Inc.
  • ChipDX, LLC
  • Circadian Technologies Limited
  • Cymogen Dx, LLC
  • Dako A/S
  • Immunohistochemistry
  • Companion Diagnostics
  • Diagnostic Biosystems (DBS)
  • DVS Sciences Inc.
  • DxTerity Diagnostics Inc.
  • Halo Healthcare Inc. (formerly NeoMatrix, LLC)
  • HistoRx, Inc.
  • Horizon Discovery Ltd
  • iKaryos Diagnostics
  • IncellDx, Inc.
  • Leica Biosystems
  • Metamark Genetics, Inc.
  • Nodality, Inc.
  • Norchip
  • Oxford Cancer Biomarkers
  • Philips Handheld Diagnostics
  • QuantuMDx
  • Theranostics Health Inc.
  • Ventana Medical Systems Inc.

CHAPTER SEVENTEEN: COMPANY PROFILES: CANCER PROTEIN MARKER SPECIALISTS

  • Arbor Vita Corporation
  • Axela Biosensors, Inc.
  • Binding Site (The)
  • BioCurex, Inc.
  • Biomerica Inc.
  • Cellmid Ltd.
  • Eutropics Pharmaceuticals
  • Fujirebio Diagnostics, Inc.
  • GeneTex
  • Gold Standard Diagnostics:
  • HealthLinx Limited
  • Immunomedics
  • MabCure Inc.
  • Matrix-Bio
  • Nano Discovery Inc.
  • Oncimmune USA LLC
  • OncoCyte Corp.
  • OncoHealth Corp
  • OPKO Health, Inc.
  • Polymedco Cancer Diagnostic Products, LLC
  • Proteomika S.L.
  • Radient Pharmaceuticals Corporation
  • Saladax Biomedical, Inc.
  • ScheBo-Biotech AG
  • Wako Diagnostics

CHAPTER EIGHTEEN: COMPANY PROFILES: MOLECULAR TEST SPECIALISTS

  • Abcodia
  • Adaptive Biotechnologies Corporation
  • Affymetrix, Inc.
  • Agilent Technologies Inc.
  • ArcticDx Inc.
  • Arrayit Diagnostics Inc.
  • Asuragen, Inc.
  • Autogenomics Inc.
  • Biocartis
  • Biodesix, Inc.
  • Cepheid
  • DiagnoCure
  • Diagnoplex SA
  • Enzo Biochem Inc.
  • Epigenomics AG
  • Falcon Genomics, Inc.
  • GeneCentric Diagnostics, Inc.
  • GeneNews Limited
  • Genetic Technologies Limited
  • Genomica S.A.U.
  • Illumina Inc.
  • Inform Genomics, Inc.
  • Ipsogen SA
  • Life Technologies
  • Med BioGene, Inc. (MBI)
  • MicroActive Project
  • MolecularMD Corporation
  • NanoString Technologies Inc.
  • Onconome, Inc
  • Orion Genomics
  • Oxford Gene Technology
  • Randox Laboratories Ltd.
  • RainDance Technologies, Inc.
  • Sequenom
  • Skyline Diagnostics B.V.
  • Soricimed Biopharma Inc. (formerly BioProspecting NB Inc.)
  • Transgenomic, Inc.
  • TrimGen Genetic Technology
  • TrovaGene, Inc.
  • VolitionRx Limited

CHAPTER NINETEEN: COMPANY PROFILES: CANCER TEST SERVICE PROVIDERS

  • 20/20 GeneSystems, Inc.
  • Acupath Laboratories, Inc.
  • Advanced Laboratory Services Inc.
  • Aetna Innovation Labs
  • Agendia BV
  • Market Expansion
  • Product News
  • AltheaDx Diagnostics, Inc.
  • ARUP Laboratories
  • Atossa Genetics, Inc.
  • BC Cancer Agency
  • Beijing Genome Institute (BGI)
  • Bio-Reference Laboratories, Inc. (BRLI)
  • bioTheranostics
  • Bostwick Laboratories
  • Cancer Genetics, Inc.
  • Caris Life Sciences
  • Castle Biosciences Inc.
  • CBLPath
  • Chronix Biomedical
  • Clarient Inc.
  • CombiMatrix Molecular Diagnostics, Inc.
  • Complete Genomics
  • deCode genetics ehf
  • DiaTech Oncology
  • Everist Genomics Inc. (EGI)
  • Exact Sciences Corp.
  • Exosome Diagnostics
  • Foundation Medicine Inc.
  • GenoID Ltd.
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Inostics GmbH
  • Insight Genetics
  • InterGenetics Inc.
  • Lab21 Limited
  • Laboratory Corporation of America Holdings (LabCorp)
  • Mayo Medical Laboratories
  • MDxHealth SA (formerly Oncomethylome Sciences)
  • Metabolistics Inc.
  • Mira Dx
  • MolecularMD Corp.
  • Myriad Genetics, Inc.
  • NeoGenomics, Inc.
  • Nuvera Biosciences, Inc.
  • NewGene
  • OncoPlex Diagnostics (formerly Expression Pathology Inc.)
  • OvaGene Oncology Inc.
  • Pacific Edge Diagnostics
  • Pathwork Diagnostics
  • Phenomenome Discoveries Inc.
  • Precision Therapeutics
  • Predictive Biosciences
  • Quest Diagnostics
  • Response Genetics, Inc.
  • RiboMed Biotechnologies, Inc.
  • Rosetta Genomics Ltd.
  • Sequenta, Inc. (formerly MLC Dx, Inc.)
  • Signal Genetics
  • Signature Diagnostics AG
  • Veracyte, Inc.
  • Vermillion Inc.

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Exchange Rate Fluctuations, 2009-2012
  • Table 1-2: Worldwide Market for Cancer In Vitro Diagnostics, 2012-2017
  • Figure 1-1: Growth In Cancer In Vitro Diagnostics Market, 2012-2017
  • Table 1-3: Worldwide Market for Histology/Cytology Cancer IVD, 2012-2017
  • Table 1-4: Worldwide Market for Immunoassays Cancer IVD, 2012-2017
  • Table 1-5: Worldwide Market for Flow Cytometry Cancer IVD, 2012-2017
  • Table 1-6: Worldwide Market for Rapid Tests Cancer IV, 2012-2017
  • Table 1-7: Worldwide Market for Molecular Assays Cancer IVD, 2012-2017
  • Table 1-8: Worldwide Market for Tissue Arrays Cancer IVD, 2012-2017
  • Table 1-9: Worldwide Market for Circulating Tumor Cells Cancer IVD, 2012-2017
  • Table 1-10: Worldwide Market for Molecular Pharmacodiagnostics Cancer IVD, 2012-2017

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Selected Test Gene Panel Targets (ALK, BRAF, C-Kit, EFGR, KRAS, P53, PIK3CA)

CHAPTER THREE: MARKET ISSUES IN THE COMMERCIALIZATION OF CANCER DIAGNOSTICS

  • Table 3-1: Cancer Incidence, Worldwide, By Cancer Type In 2008
  • Figure 3-1: World Cancer Test Sales, Percentage by Region (N. America, EU, Japan, ROW)
  • Table 3-2: World Cancer Test Market by Region (N. America, EU, Japan, ROW), 2007-2012
  • Table 3-3: Cancer Death Rates, by Region (Africa, Americas, Europe, Southeast Asia, Western Pacific, China, East Mediterranean, India), 2008
  • Table 3-4: Selected Cancer Company Lab Service Expansions
  • Table 3-5: Revenues For A Selection Of Molecular Test Service Labs, Worldwide, 2012, $ Million (Estimated)
  • Table 3-6: Selected Hospital Cancer Test Services
  • Table 3-7: Selected IVD and Pharmaceutical Company Collaborations

CHAPTER FOUR: TECHNOLOGICAL TRENDS THAT ENABLE THE FUTURE OF CANCER DIAGNOSTICS

  • Table 4-1: Selected Multiplexed Cancer Test And Service Innovations
  • Table 4-2: Selected Non-Invasive Cancer Test Innovations
  • Table 4-3: Selected Information Technology Innovations In Molecular Testing
  • Table 4-4: Selected App Products
  • Table 4-5: Selected Cancer Tests using Mass Spectrometry
  • Table 4-6: Selected Companies Involved In Chromosomal Analysis Of Cancer Cells
  • Table 4-7: Selected Chromosome-Based Cancer Tests And Services
  • Table 4-8: Sequencing Platforms Available
  • Table 4-9: Selected Sequencing-Based Tests And Test Services
  • Table 4-10: Selected Sample Preparation Systems for Sequencing Tests
  • Table 4-11: Selected Nucleic Acid Sample Preparation Products
  • MARKET OVERVIEW - MARKET ANALYSIS
  • Table 5-1: Worldwide Market for Selected Cancer In Vitro Diagnostics (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, CTCs, Pharmacodiagnostics, Circulating Plasma DNA), 2012-2017
  • Table 5-2: Revenues of Selected Cancer Testing Companies
  • Table 5-3: Cancer Diagnostics and the Top Tier of IVD Companies
  • Table 5-4: Selected Acquisitions, Mergers And New Cancer Test Investments
  • Table 5-5: Selected Cancer Test Collaborations
  • Table 5-6: Selected Cancer Test Distribution Agreements
  • Table 5-7: Selected Cancer Test Licensing Agreements
  • Table 5-8: Selected POL-appropriate Cancer Test Systems

CHAPTER SIX: CANCER TESTS IN CLINICAL CHEMISTRY

  • Table 6-1: Selected Tissue Function Clinical Chemistry Tests
  • Table 6-2: Major Players For Clinical Chemistry Analyzers And Reagents

CHAPTER SEVEN: IMMUNOASSAY CANCER TESTS

  • Table 7-1: Selected Widely Used Tumor Markers
  • Table 7-2: Selected Cancer Immunoassay Technology Innovations
  • Table 7-4: Cancer Immunoassay Sales, Lab-based (PSA, CEA, CA 125, AFP, Others), 2012-2017
  • Table 7-5: Rapid Cancer Test Sales by Test Category (FOB, PSA, NMP22, Other) Worldwide 2012-2017

CHAPTER EIGHT: TISSUE- AND CELL-BASED CANCER TESTS

  • Table 8-1: Selected Histology Test Services
  • Table 8-2: Selected Innovations In Tissue-Based Cancer Tests
  • Table 8-3: Worldwide Histology/Cytology Sales (Pap, in situ hybridization, immunohistochemistry, HPV, Tissue Microarrays), 2012-2017
  • Table 8-4: Revenues of the Major Histology Companies, 2009-2012
  • Table 8-5: Selected Major Protein And Molecular Markers
  • Table 8-6: Selected Technology Innovations In Cancer Testing
  • Table 8-8: Selected HPV Test Innovations
  • Table 8-9: Selected Tissue Microarray Products
  • Table 8-10: Selected Live Cell Cancer Tests
  • Table 8-11: Selected New Cancer Tests and Technologies

CHAPTER NINE: CANCER TESTS IN FLOW CYTOMETRY

  • Table 9-1: Selected flow cytometry innovations for cancer testing

CHAPTER TEN: CIRCULATING TUMOR CELLS IN CANCER DIAGNOSTICS

  • Table 10-1: Selected CTC Capture And Analysis Systems

CHAPTER ELEVEN: CANCER MOLECULAR ASSAYS

  • Table 11-1: Selected Commercial Molecular Cancer Tests
  • Table 11-2: Selected Molecular Instrumentation Innovations
  • Table 11-3: Selected RNA-Based Cancer Tests
  • Table 11-4: Selected Methylated DNA tests

CHAPTER TWELVE: PERSONALIZED CANCER TESTING ADVANCES IN PRECISION

  • Table 12-1: Most Common Cancer Drug/Gene Mutation Combinations
  • Table 12-2: Major Protein And Molecular Markers Used In Tissue Staining
  • Table 12-3: Selected Pharmacodiagnostic Histology Tests
  • Table 12-4: Selected Chemotherapy Resistance Tests
Back to Top